Developer docs
API playgroundTry for free, no card

Search company profiles

BioCircuit Technologies

Full company profile

uuid0000ngp

Namestring
BioCircuit Technologies
Legal namestring
BioCircuit Technologies, Inc.
Websiteurl
biocircuit.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

BioCircuit Technologies is a privately held medical device company headquartered in Atlanta, Georgia, that develops and commercializes devices for monitoring, controlling, and repairing peripheral nerves. The company was spun off from Axion Biosystems in June 2019 and currently employs 11–50 people. Its flagship product, Nerve Tape®, received FDA 510(k) clearance in July 2022 as the first sutureless nerve repair device on the U.S. market. The device combines a porcine small intestinal submucosa (SIS) biomaterial wrap with integrated Nitinol microhooks (penetration depth under 0.5mm) that attach to the outer sheath of severed nerves, enabling coaptation without microsutures. Clinical data demonstrates 4.8x faster repair times and 2.6x stronger repairs compared to microsuture, with 97% alignment success among surgeons and trainees. The second product, ConformaWrap®, launched in September 2025, is an SIS-based nerve protector for use in peripheral nerve injuries without gap. BioCircuit is also developing a Reflex Operant Conditioning (ROC) system in collaboration with MUSC and NCAN for spasticity management in spinal cord injury patients.

The company's go-to-market is an enterprise field sales motion targeting surgeons and hospitals in the United States, supplemented by direct email ordering, conference sales, and clinical education programs including the Breast Neurotization Visitation Program. BioCircuit generates revenue through one-time hardware sales of single-use surgical devices purchased by hospitals and surgical centers. Pricing is not publicly disclosed; orders are placed via email or through sales representatives. The company has secured approximately $9 million in Series Seed funding (September 2022, from Alsora Capital and GRA Venture Fund) plus approximately $6.6 million in NIH grant funding across three cycles (2021, 2023, 2024). Within 16 months of first human implants in June 2024, over 3,500 Nerve Tape devices had been implanted, earning the company a place on the 2025 Inc. 5000 list. Customer evidence spans leading academic medical centers including Weill Cornell Medicine, Mayo Clinic Arizona, RUSH University Medical Center, Beaumont Hospital, and UC Davis.

Short descriptiontext

BioCircuit Technologies develops and commercializes FDA-cleared peripheral nerve repair devices, including Nerve Tape (the first sutureless nerve coaptation connector) and ConformaWrap (an SIS nerve protector), serving plastic, reconstructive, hand, and head-and-neck surgeons at U.S. hospitals and surgical centers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersAtlanta, United States
HQ citystring
Atlanta
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
peripheral nerve repair, sutureless nerve device, medical device manufacturing, neuromodulation systems, electrophysiology devices
Industry1 code
PRIMARYHLAHAEAD
Neurosurgical Implants & Cranial/CMF (Cranial Plates, Dural Repair, Shunts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
NAICS code2 codes
  • Surgical Appliance and Supplies Manufacturing339113
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code2 codes
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
  • Surgical & Medical Instruments & Apparatus3841
Product category
Peripheral Nerve Repair Medical Devices
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Medical Device Sales
TypeHardware Sales
Description

BioCircuit generates revenue through the sale of medical devices including Nerve Tape and ConformaWrap. These are one-time use surgical devices purchased by hospitals and surgical centers for use in nerve repair procedures.

biocircuit.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales
Pricing details1 tier
1Direct ordering - quote-based pricing
ModelOtherBilling cadencePay-as-you-go
Notes

Pricing not publicly disclosed. Orders placed via email to orders@biocircuit.com or through sales representative contact form.

biocircuit.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1Nerve Tape
Description

The first FDA-cleared sutureless device for nerve repair. A sutureless connector that simplifies nerve repair with flexible biomaterial and integrated microscale hooks.

biocircuit.com
+1 more record
Core offering1 text field

BioCircuit Technologies develops and commercializes FDA-cleared medical devices for peripheral nerve repair and neuromodulation. Its flagship product, Nerve Tape, is the first FDA-cleared sutureless nerve repair device that combines porcine Small Intestinal Submucosa (SIS) biomaterial with integrated Nitinol microhooks to perform sutureless nerve coaptation. The company also offers ConformaWrap, a porcine SIS nerve protection wrap, and is developing a Reflex Operant Conditioning (ROC) system for spasticity management.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 4.8x faster repair time compared to microsuture (1.6 ± 0.8 min vs 7.2 ± 3.6 min)
+5 more records
Product overview1 text field

BioCircuit Technologies offers a focused portfolio of two FDA-cleared medical devices for peripheral nerve repair: Nerve Tape® and ConformaWrap®. Nerve Tape® is the company's flagship product - the first FDA-cleared sutureless nerve repair device that uses flexible biomaterial with integrated Nitinol microhooks for quick, sutureless nerve coaptation. ConformaWrap® is a complementary SIS-based nerve wrap product that provides protective barrier coverage for nerve protection without requiring sutures. Together, these products address different aspects of nerve repair and protection, from direct coaptation (Nerve Tape) to protective wrapping (ConformaWrap).

Product and service2 records
1Nerve Tape®
CategoryPeripheral nerve repair medical device
Description

The first FDA-cleared sutureless device for peripheral nerve repair. Nerve Tape combines a porcine Small Intestinal Submucosa (SIS) wrap with integrated Nitinol microhooks that securely attach to the outer sheath of severed nerves with penetration depth less than 0.5mm, providing a strong hold while distributing tension across the repair site. It eliminates the need for microsuturing, reducing repair time and minimizing tissue damage. Indicated for peripheral nerve repair procedures across plastic surgery, hand/orthopedic, oral/maxillofacial, head & neck, breast reconstruction, and lower extremity applications.

2ConformaWrap®
CategoryPeripheral nerve protection medical device
Description

A porcine Small Intestinal Submucosa (SIS) nerve protector wrap that provides surgeons with a customizable, easy-to-use solution for nerve protection. ConformaWrap may eliminate the need for suturing to reduce operative time and complexity, and is designed to prevent the nerve from reattaching to surrounding tissue and reduce the risk of post-surgical scarring. Indicated for management of peripheral nerve injuries where there is no gap.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaborative partnership for development of the Reflex Operant Conditioning (ROC) system for spasticity management in spinal cord injury patients.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration partner for ROC system development targeting spasticity management and neurorehabilitation research.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership with Global Nerve Foundation to advance nerve repair and improve patient outcomes through impactful, innovative projects. Joint webinars and educational programs.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Synapse Biomedical develops implanted neurostimulation systems (e.g., NeuRx for diaphragm stimulation) — an emerging neurostimulation peer relevant to BioCircuit's ROC platform targeting spasticity management.

TypeBroad incumbent
Description

Medtronic operates a large neuromodulation franchise (spinal cord stimulators, deep brain stimulators, peripheral nerve stimulators) and competes broadly with BioCircuit's developing ROC neuromodulation platform.

TypeEmerging player
Description

Polyganics develops bioresorbable nerve repair devices (e.g., NEUROLAC) for peripheral nerve gaps, representing a European emerging competitor with overlapping biomaterial-based nerve repair technology.

TypeDirect peer
Description

Axogen is the dominant player in peripheral nerve repair, offering Avance nerve grafts, AcroVal, and Connector-Assisted devices — the established incumbent against which BioCircuit's Nerve Tape competes directly for the same surgical nerve coaptation workflow.

TypeBroad incumbent
Description

Abbott's neuromodulation business (Proclaim DRG and SCS systems) makes it a broad incumbent in peripheral nerve and spinal cord stimulation, with potential overlap with BioCircuit's future ROC neuromodulation pipeline.

TypeEmerging player
Description

Checkpoint Surgical makes nerve stimulation and localization devices for intraoperative use — adjacent to BioCircuit's nerve repair focus and relevant to the same surgeon customers (hand, plastic, orthopedic surgeons).

TypeBroad incumbent
Description

Stryker is a large diversified medical device company with surgical, orthopedic, and neurosurgery franchises. It competes in nerve repair and adjacent surgical consumables where BioCircuit sells Nerve Tape and ConformaWrap.

TypeBroad incumbent
Description

Boston Scientific operates a sizeable neuromodulation franchise (WaveWriter, Vercise) addressing pain and movement disorders — a relevant broad incumbent against BioCircuit's pipeline neuromodulation efforts.

TypeBroad incumbent
Description

Baxter offers a range of surgical and biosurgery products (including hemostats and sealants relevant to peripheral nerve procedures) — a broad incumbent competing in the surgical consumables category where BioCircuit sells its disposable devices.

TypeBroad incumbent
Description

Integra offers NeuraGen nerve guide and other regenerative peripheral nerve repair products within a broad surgical and neurosurgery portfolio. It competes with BioCircuit in nerve repair while serving many other surgical specialties.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers9 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

BioCircuit Technologies

Peripheral Nerve Repair Medical Devicesbiocircuit.com

BioCircuit Technologies develops and commercializes FDA-cleared peripheral nerve repair devices, including Nerve Tape (the first sutureless nerve coaptation connector) and ConformaWrap (an SIS nerve protector), serving plastic, reconstructive, hand, and head-and-neck surgeons at U.S. hospitals and surgical centers.

What BioCircuit Technologies does

BioCircuit Technologies is a privately held medical device company headquartered in Atlanta, Georgia, that develops and commercializes devices for monitoring, controlling, and repairing peripheral nerves. The company was spun off from Axion Biosystems in June 2019 and currently employs 11–50 people. Its flagship product, Nerve Tape®, received FDA 510(k) clearance in July 2022 as the first sutureless nerve repair device on the U.S. market. The device combines a porcine small intestinal submucosa (SIS) biomaterial wrap with integrated Nitinol microhooks (penetration depth under 0.5mm) that attach to the outer sheath of severed nerves, enabling coaptation without microsutures. Clinical data demonstrates 4.8x faster repair times and 2.6x stronger repairs compared to microsuture, with 97% alignment success among surgeons and trainees. The second product, ConformaWrap®, launched in September 2025, is an SIS-based nerve protector for use in peripheral nerve injuries without gap. BioCircuit is also developing a Reflex Operant Conditioning (ROC) system in collaboration with MUSC and NCAN for spasticity management in spinal cord injury patients.

The company's go-to-market is an enterprise field sales motion targeting surgeons and hospitals in the United States, supplemented by direct email ordering, conference sales, and clinical education programs including the Breast Neurotization Visitation Program. BioCircuit generates revenue through one-time hardware sales of single-use surgical devices purchased by hospitals and surgical centers. Pricing is not publicly disclosed; orders are placed via email or through sales representatives. The company has secured approximately $9 million in Series Seed funding (September 2022, from Alsora Capital and GRA Venture Fund) plus approximately $6.6 million in NIH grant funding across three cycles (2021, 2023, 2024). Within 16 months of first human implants in June 2024, over 3,500 Nerve Tape devices had been implanted, earning the company a place on the 2025 Inc. 5000 list. Customer evidence spans leading academic medical centers including Weill Cornell Medicine, Mayo Clinic Arizona, RUSH University Medical Center, Beaumont Hospital, and UC Davis.

BioCircuit Technologies firmographics

Firmographics
Name
BioCircuit Technologies
Legal name
BioCircuit Technologies, Inc.
Website
https://biocircuit.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
11–50 employees
Short description
BioCircuit Technologies develops and commercializes FDA-cleared peripheral nerve repair devices, including Nerve Tape (the first sutureless nerve coaptation connector) and ConformaWrap (an SIS nerve protector), serving plastic, reconstructive, hand, and head-and-neck surgeons at U.S. hospitals and surgical centers.
Ownership category
akta.pro rank

BioCircuit Technologies industry classification

Industry
Product category
Peripheral Nerve Repair Medical Devices
NAICS
Surgical Appliance and Supplies Manufacturing (339113), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAEAD
Neurosurgical Implants & Cranial/CMF (Cranial Plates, Dural Repair, Shunts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)

Keywords

  • Peripheral nerve repair
  • Sutureless nerve device
  • Medical device manufacturing
  • Neuromodulation systems
  • Electrophysiology devices

Where BioCircuit Technologies is headquartered

Location

Headquarters

HQ city
Atlanta
HQ country
United States
HQ region
North America

Offices1 record

Markets served

BioCircuit Technologies business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales

Revenue model

  1. Medical Device Sales: BioCircuit generates revenue through the sale of medical devices including Nerve Tape and ConformaWrap. These are one-time use surgical devices purchased by hospitals and surgical centers for use in nerve repair procedures.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goDirect ordering - quote-based pricing

Go-to-market motion2 records

Distribution channels3 records

Marketing channels7 records

BioCircuit Technologies product offering

Product offering

Core offering

BioCircuit Technologies develops and commercializes FDA-cleared medical devices for peripheral nerve repair and neuromodulation. Its flagship product, Nerve Tape, is the first FDA-cleared sutureless nerve repair device that combines porcine Small Intestinal Submucosa (SIS) biomaterial with integrated Nitinol microhooks to perform sutureless nerve coaptation. The company also offers ConformaWrap, a porcine SIS nerve protection wrap, and is developing a Reflex Operant Conditioning (ROC) system for spasticity management.

Product overview

BioCircuit Technologies offers a focused portfolio of two FDA-cleared medical devices for peripheral nerve repair: Nerve Tape® and ConformaWrap®. Nerve Tape® is the company's flagship product - the first FDA-cleared sutureless nerve repair device that uses flexible biomaterial with integrated Nitinol microhooks for quick, sutureless nerve coaptation. ConformaWrap® is a complementary SIS-based nerve wrap product that provides protective barrier coverage for nerve protection without requiring sutures. Together, these products address different aspects of nerve repair and protection, from direct coaptation (Nerve Tape) to protective wrapping (ConformaWrap).

Differentiator

Problem solved

Functional benefit

Brands

  • Nerve Tape: The first FDA-cleared sutureless device for nerve repair. A sutureless connector that simplifies nerve repair with flexible biomaterial and integrated microscale hooks.
  • ConformaWrap

Products and services

  • Nerve Tape® The first FDA-cleared sutureless device for peripheral nerve repair. Nerve Tape combines a porcine Small Intestinal Submucosa (SIS) wrap with integrated Nitinol microhooks that securely attach to the outer sheath of severed nerves with penetration depth less than 0.5mm, providing a strong hold while distributing tension across the repair site. It eliminates the need for microsuturing, reducing repair time and minimizing tissue damage. Indicated for peripheral nerve repair procedures across plastic surgery, hand/orthopedic, oral/maxillofacial, head & neck, breast reconstruction, and lower extremity applications.
  • ConformaWrap® A porcine Small Intestinal Submucosa (SIS) nerve protector wrap that provides surgeons with a customizable, easy-to-use solution for nerve protection. ConformaWrap may eliminate the need for suturing to reduce operative time and complexity, and is designed to prevent the nerve from reattaching to surrounding tissue and reduce the risk of post-surgical scarring. Indicated for management of peripheral nerve injuries where there is no gap.

Quantifiable outcome

  • 4.8x faster repair time compared to microsuture (1.6 ± 0.8 min vs 7.2 ± 3.6 min)
  • +5 more outcomes

Companies that use BioCircuit Technologies

Customer profile

Named customers9 records

Segments5 records

Ideal customer profiles4 records

BioCircuit Technologies technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

BioCircuit Technologies partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • MUSC (Medical University of South Carolina)coreStrategic or Co-development PartnerCollaborative partnership for development of the Reflex Operant Conditioning (ROC) system for spasticity management in spinal cord injury patients.
  • NCAN (Neural Control of Human Movement)coreStrategic or Co-development PartnerCollaboration partner for ROC system development targeting spasticity management and neurorehabilitation research.
  • Global Nerve FoundationcoreStrategic or Co-development PartnerPartnership with Global Nerve Foundation to advance nerve repair and improve patient outcomes through impactful, innovative projects. Joint webinars and educational programs.

Scale indicators9 records

Recent moves7 records

Expansion highlights5 records

BioCircuit Technologies competitors and assessment

Company assessment

Emerging players

  • Synapse Biomedical: Synapse Biomedical develops implanted neurostimulation systems (e.g., NeuRx for diaphragm stimulation) — an emerging neurostimulation peer relevant to BioCircuit's ROC platform targeting spasticity management.
  • Polyganics: Polyganics develops bioresorbable nerve repair devices (e.g., NEUROLAC) for peripheral nerve gaps, representing a European emerging competitor with overlapping biomaterial-based nerve repair technology.
  • Checkpoint Surgical: Checkpoint Surgical makes nerve stimulation and localization devices for intraoperative use — adjacent to BioCircuit's nerve repair focus and relevant to the same surgeon customers (hand, plastic, orthopedic surgeons).

Broad incumbents

  • Medtronic: Medtronic operates a large neuromodulation franchise (spinal cord stimulators, deep brain stimulators, peripheral nerve stimulators) and competes broadly with BioCircuit's developing ROC neuromodulation platform.
  • Abbott: Abbott's neuromodulation business (Proclaim DRG and SCS systems) makes it a broad incumbent in peripheral nerve and spinal cord stimulation, with potential overlap with BioCircuit's future ROC neuromodulation pipeline.
  • Stryker: Stryker is a large diversified medical device company with surgical, orthopedic, and neurosurgery franchises. It competes in nerve repair and adjacent surgical consumables where BioCircuit sells Nerve Tape and ConformaWrap.
  • Boston Scientific: Boston Scientific operates a sizeable neuromodulation franchise (WaveWriter, Vercise) addressing pain and movement disorders — a relevant broad incumbent against BioCircuit's pipeline neuromodulation efforts.
  • Baxter International: Baxter offers a range of surgical and biosurgery products (including hemostats and sealants relevant to peripheral nerve procedures) — a broad incumbent competing in the surgical consumables category where BioCircuit sells its disposable devices.
  • Integra LifeSciences: Integra offers NeuraGen nerve guide and other regenerative peripheral nerve repair products within a broad surgical and neurosurgery portfolio. It competes with BioCircuit in nerve repair while serving many other surgical specialties.

Direct peers

  • Axogen: Axogen is the dominant player in peripheral nerve repair, offering Avance nerve grafts, AcroVal, and Connector-Assisted devices — the established incumbent against which BioCircuit's Nerve Tape competes directly for the same surgical nerve coaptation workflow.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

BioCircuit Technologies social profiles

Digital presence

BioCircuit Technologies compliance and trust

Trust signal

Compliance1 record

BioCircuit Technologies financial estimates

Financial estimate

Revenue estimate

Valuation estimate

BioCircuit Technologies leadership team

Management profile

Number of profiles

Profiles3 records

BioCircuit Technologies funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

BioCircuit Technologies M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BioCircuit Technologies

What does BioCircuit Technologies do?

BioCircuit Technologies develops and commercializes FDA-cleared medical devices for peripheral nerve repair and neuromodulation. Its flagship product, Nerve Tape, is the first FDA-cleared sutureless nerve repair device that combines porcine Small Intestinal Submucosa (SIS) biomaterial with integrated Nitinol microhooks to perform sutureless nerve coaptation. The company also offers ConformaWrap, a porcine SIS nerve protection wrap, and is developing a Reflex Operant Conditioning (ROC) system for spasticity management.

Is BioCircuit Technologies a public or private company?

BioCircuit Technologies is a private company. It is classified as venture growth investor backed and is currently operating.

When was BioCircuit Technologies founded?

BioCircuit Technologies was founded in 2019. It employs 11 to 50 people.

Where is BioCircuit Technologies based?

BioCircuit Technologies is headquartered in Atlanta, United States, in the North America region.

How does BioCircuit Technologies make money?

One revenue line is on record: medical Device Sales.

Who are BioCircuit Technologies's main competitors?

Emerging players on record are Synapse Biomedical, Polyganics and Checkpoint Surgical. Broad incumbents are Medtronic, Abbott, Stryker, Boston Scientific, Baxter International and Integra LifeSciences. Axogen is listed as a direct peer.

Does BioCircuit Technologies have an API?

No public API is recorded for BioCircuit Technologies.

What industry is BioCircuit Technologies in?

BioCircuit Technologies's product category is Peripheral Nerve Repair Medical Devices. Its primary akta.pro industry code is HLAHAEAD, Neurosurgical Implants & Cranial/CMF (Cranial Plates, Dural Repair, Shunts). Its NAICS code is 339113 and its SIC code is 3842.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The Motley FoolAxogen (AXGN) Q3 2026 Earnings Call TranscriptAxogen reported Q3 2026 revenue of $75.8 million, up 26.2% year over year, with adjusted net income of $13.1 million. The company completed its $200 million acquisition of BioCircuit Technologies on Oct. 1, 2026, and raised full-year 2026 revenue guidance to at least $290 million, including $7 million from BioCircuit.The Motley FoolAxogen (AXGN) Q3 2026 Earnings Call TranscriptAxogen reported Q3 2026 revenue of $75.8 million, up 26.2% year over year, with adjusted net income of $13.1 million. The company completed its $200 million acquisition of BioCircuit Technologies on Oct. 1, 2026, and raised full-year 2026 revenue guidance to at least $290 million, including $7 million from BioCircuit.Seeking AlphaAxogen forecasts at least $290M 2026 revenue, adds $7M from BioCircuit while planning prostate market development in 2027 (NASDAQ:AXGN)Axogen reported Q3 2026 revenue of $75.8 million, up 26.2% year-over-year, and revised full-year 2026 guidance to at least $290 million, including $7 million from BioCircuit. The company completed the BioCircuit acquisition and plans to begin prostate nerve reconstruction market development in 2027, which is not included in current guidance.Investing.comAxogen completes acquisition of BioCircuit TechnologiesAxogen completed its acquisition of BioCircuit Technologies, a medical device company that developed NerveTape, an FDA-cleared sutureless nerve repair device. Axogen expects BioCircuit to contribute about $6 million to fourth-quarter 2026 revenue and $34 million to 2027 revenue, not included in its full-year 2026 guidance. The company plans to commercialize the technology using its direct sales and hospital contracting capabilities.Quiver QuantitativeAxogen Completes Acquisition of BioCircuit Technologies, Expanding Peripheral Nerve Repair Portfolio | AXGN Stock NewsAxogen completed its acquisition of BioCircuit Technologies, adding NerveTape, the first FDA-cleared sutureless nerve repair device. The company expects BioCircuit to contribute about $6 million in Q4 2026 and $34 million in 2027, not included in prior guidance. Axogen maintains a projected gross margin of at least 73% and free cash positive in 2026.Investing.comAxogen completes acquisition of BioCircuit TechnologiesAxogen completed its acquisition of BioCircuit Technologies, a medical device company that developed NerveTape, an FDA-cleared sutureless device for nerve repair. The company expects BioCircuit to contribute about $6 million to fourth-quarter 2026 revenue and $34 million to 2027 revenue, not included in its full-year 2026 guidance.The future of tradingAxogen completes acquisition of BioCircuit TechnologiesAxogen completed the acquisition of privately held BioCircuit Technologies, adding its NerveTape device for sutureless peripheral nerve repair. BioCircuit is expected to contribute about $6 million in revenue in Q4 2026 and about $34 million in 2027, not included in Axogen's 2026 outlook. The company reiterated its full-year 2026 gross margin guidance of at least 73% and expects to remain free cash flow positive.The future of tradingAxogen Completes Acquisition of BioCircuit Technologies, Adding NerveTape™, the First FDA Cleared Device for Sutureless Peripheral Nerve RepairAxogen completed its acquisition of BioCircuit Technologies, adding NerveTape, the first FDA-cleared sutureless device for peripheral nerve repair. The company expects BioCircuit to contribute about $6 million in Q4 2026 and $34 million in 2027 revenue, not included in its full-year guidance.FinancialContent Business PageAxogen Completes Acquisition of BioCircuit Technologies, Adding NerveTape™, the First FDA Cleared Device for Sutureless Peripheral Nerve RepairAxogen completed its acquisition of BioCircuit Technologies, adding NerveTape, the first FDA-cleared sutureless device for peripheral nerve repair. The company expects BioCircuit to contribute about $6 million in Q4 2026 and $34 million in 2027 revenue, not included in its full-year 2026 guidance.Stock TitanAxogen Completes BioCircuit Acquisition, Adds NerveTapeAxogen completed its acquisition of BioCircuit Technologies, adding NerveTape, the first FDA-cleared sutureless peripheral nerve repair device. The company expects BioCircuit to contribute about $6 million in Q4 2026 and $34 million in 2027, not included in its 2026 revenue growth guidance.